Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04352595 | A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients | PHASE2 | COMPLETED | 148 | — | — | Apr 24, 2020 | Apr 2, 2021 | Mar 1, 2024 | 2 | China |
EASI Clinical Signs Severity Sum Score change from Baseline at Day 29
| Arm | Type | Description |
|---|---|---|
| 1% Hemay808 | EXPERIMENTAL | - |
| 3% Hemay808 | EXPERIMENTAL | - |
| 7% Hemay808 | EXPERIMENTAL | - |
| vehicle | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Hemay808 | DRUG | Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor. |
Inclusion Criteria: * ≥18 years old and ≤65 years old, gender is not limited; * It met the diagnostic criteria for atopic dermatitis (AD) of Hanifin\&Rajka, and the history of AD before screening was ≥6 months; * The investigator's overall score (IGA) at the screening period/baseline visit was 2-3;...